JPS6056700B2 - Pharmaceutical compositions comprising new compounds, and methods for producing and using the same - Google Patents
Pharmaceutical compositions comprising new compounds, and methods for producing and using the sameInfo
- Publication number
- JPS6056700B2 JPS6056700B2 JP52010599A JP1059977A JPS6056700B2 JP S6056700 B2 JPS6056700 B2 JP S6056700B2 JP 52010599 A JP52010599 A JP 52010599A JP 1059977 A JP1059977 A JP 1059977A JP S6056700 B2 JPS6056700 B2 JP S6056700B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- trans
- fluoro
- compound
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229910001868 water Inorganic materials 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 13
- 150000001412 amines Chemical class 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 239000001961 anticonvulsive agent Substances 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 230000001773 anti-convulsant effect Effects 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 229960003965 antiepileptics Drugs 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 239000012433 hydrogen halide Substances 0.000 claims description 3
- 229910000039 hydrogen halide Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 229940125681 anticonvulsant agent Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- RTSIUKMGSDOSTI-SNAWJCMRSA-N (e)-3-(3-fluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(F)=C1 RTSIUKMGSDOSTI-SNAWJCMRSA-N 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 229940099112 cornstarch Drugs 0.000 description 5
- 238000000921 elemental analysis Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000007891 compressed tablet Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960004016 sucrose syrup Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- YEMUSDCFQUBPAL-SNAWJCMRSA-N (e)-3-(3-bromophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(Br)=C1 YEMUSDCFQUBPAL-SNAWJCMRSA-N 0.000 description 1
- HGQSKTQYEWJJRZ-SNAWJCMRSA-N (e)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl chloride Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(Cl)=O)=C1 HGQSKTQYEWJJRZ-SNAWJCMRSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000009017 Athetosis Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 238000003684 Perkin reaction Methods 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000006680 Reformatsky reaction Methods 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- APEJMQOBVMLION-UHFFFAOYSA-N cinnamamide Chemical class NC(=O)C=CC1=CC=CC=C1 APEJMQOBVMLION-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 201000005108 complex partial epilepsy Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- SIIJRCRHAIMFNT-UHFFFAOYSA-N cyclopropanamine;hydrochloride Chemical compound Cl.NC1CC1 SIIJRCRHAIMFNT-UHFFFAOYSA-N 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- -1 nickel peroxide Chemical class 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
- C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Description
【発明の詳細な説明】
本発明は医薬上有用な性質を有する化学物質に関するも
のである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to chemical substances having pharmaceutically useful properties.
本発明は特にシナマミド類、その合成、これを含有する
ところの製薬、およびその医療上の使用に関連する。下
記に定める式(1)で示されるシナマミドは、以下にか
かげる確立された医薬実験におけるマウスに対する効果
が示すように、啼乳動物に対して抗けいれん活性を有す
ることが見い出されている。The invention particularly relates to cinnamamides, their synthesis, pharmaceuticals containing them, and their medical uses. Sinamamide, represented by formula (1) as defined below, has been found to have anticonvulsant activity in mammals, as shown by its effect on mice in established pharmaceutical experiments mentioned below.
1 マウスにおける最大電気ショック実験(Maxim
aIElectr′0sh0ckTest,MES)W
OOdburyおよびDaveupOrLにより、Ar
chint.PharmacOdyu,第92編,97
−107頁(1952年)に記載の方法。1 Maximum electric shock experiment in mice (Maxim
aIElectr′0sh0ckTest,MES)W
Ar by OOdbury and DaveupOrL
chint. PharmacOdyu, 92nd edition, 97
- The method described on page 107 (1952).
2 マウスにおけるメトラゾール発作実験(Metr′
AzOlSeizureTest,MET)S′Vvi
nyard,BrOwnおよびCOOdmanにより、
J.PhamacOl,Exp.Therap.lO6
巻319−330頁(195拝)に記載の方法。2. Metrazol seizure experiment in mice (Metr'
AzOlSeizureTest,MET)S'Vvi
by nyard, BrOwn and COOdman.
J. PharmacOl, Exp. Therap. lO6
The method described in Volume 319-330 (195th edition).
式1において、Xはフルオロまたはトリフルオロメチル
であり、そしてRは3〜6個の炭素原子を有するシクロ
アルキルである。In formula 1, X is fluoro or trifluoromethyl and R is cycloalkyl having 3 to 6 carbon atoms.
式(1)で示される化合物のうちトランス構造を有する
のが好ましい。Among the compounds represented by formula (1), those having a trans structure are preferred.
式(1)の化合物の中でRがシクロプロピルである化合
物が好ましい。Among the compounds of formula (1), compounds in which R is cyclopropyl are preferred.
式(1)で示される化合物のうち以下の化合物が特にあ
げられる:3−フルオローN−シクロプロピルシナマミ
ド;3−フルオローN−シクロペンチルシナマミド;3
−フルオローN−シクロヘキシルシナマミド;3−フル
オローN−シクロブチルシナマミド;3−トリフルオロ
メチルーN−シクロプロピルシナマミド;3−トリフル
オロメチルーN−シクロブチルシナマミド;3−トリフ
ルオロメチルーN−シクロペンチルシナマミド;3−ト
リフルオロメチルーN−シクロヘキシルシナマミド;式
(1)で示される化合物は、類似構造を有するシナマミ
ド類の任意の既知の合成方法により製造できる。Among the compounds represented by formula (1), the following compounds may be mentioned in particular: 3-fluoro N-cyclopropyl cinamamide; 3-fluoro N-cyclopentyl cinamamide;
-Fluoro N-cyclohexylcinamamide; 3-fluoro N-cyclobutylcinamamide; 3-trifluoromethyl-N-cyclopropylcinamamide; 3-trifluoromethyl-N-cyclobutylcinamamide; 3-trifluoromethyl-N-cyclopentyl Sinamamide; 3-trifluoromethyl-N-cyclohexylcinamamide; The compound represented by formula (1) can be produced by any known synthesis method for cinamamides having a similar structure.
たとえばアミンRNH2(ただしRは式(1)の場合と
同じ)を、相当する式(■):m一X−PhCH=CH
CO2H(ただしxは式(1)に”定めるものとする)
で示される酸またはその反応性誘導体、たとえばチオエ
ステルまたはエステル(たとえば1ないし4個の炭素原
子を有するアルキルのアルキルエステルまたはチオエス
テル)、アミド、酸ハライド(たとえば塩化酸)または
酸無水物でのアシル化により、この化合物を製造するこ
とができる。アシル化剤の性質にもとづいて広範囲の反
応条件を用いることができるが、一般に各反応物を共に
、好ましくは不活性な液体媒質たとえばエーテル、ベン
ゼン、トルエンまたはシクロヘキサン中で還流する。最
も好都合な合成方法は、酸クロリドと適するアミンとの
反応である。For example, the amine RNH2 (where R is the same as in formula (1)) is converted to the corresponding formula (■): m-X-PhCH=CH
CO2H (However, x shall be defined in formula (1))
Acylation with acids of the formula or reactive derivatives thereof, such as thioesters or esters (e.g. alkyl esters or thioesters of alkyls having 1 to 4 carbon atoms), amides, acid halides (e.g. chlorinated acids) or acid anhydrides. This compound can be produced by: Although a wide range of reaction conditions can be used based on the nature of the acylating agent, generally each reactant is refluxed together, preferably in an inert liquid medium such as ether, benzene, toluene or cyclohexane. The most convenient method of synthesis is the reaction of the acid chloride with a suitable amine.
1当量のハライドと2当量ないしそれ以上のアミンとを
使用するのが好ましいが、アミンのモル過剰分は他の塩
基たとえば、トリエチルアミン、ピリジン、ジメチルア
ニリン、もしくは炭酸カリウムまたは炭酸ナトリウムで
代用してもよい。It is preferred to use one equivalent of halide and two or more equivalents of amine, although the molar excess of amine may be substituted with other bases such as triethylamine, pyridine, dimethylaniline, or potassium or sodium carbonate. good.
広範囲の極性または非極性の液体媒質(水、アルカノー
ルたとえばメタノール、エタノール等、エーテル、ジオ
キサン、ベンゼン、トルエン、キシレン、石油エーテル
、シクロヘキサン、テトラヒドロフラン、クロロホルム
および四塩化炭素を含む)が使用できる。また温度条件
も広範囲(たとえば−10℃から反応混合物の還流温度
まで)にて実施できる。式(1)で示される化合物はさ
らに、式(■)および式(■)で示される相当するアル
コールまたはアルデヒドを、温度1(代)以下にて適当
なアミンRNH2と、過酸化ニッケルの存在下で不活性
な液体媒質たとえばエーテル、ベンゼン、テトラヒドロ
フランまたは石油炭化水素中で反応させることにより直
接製造できる。A wide variety of polar or non-polar liquid media can be used, including water, alkanols such as methanol, ethanol, etc., ethers, dioxane, benzene, toluene, xylene, petroleum ether, cyclohexane, tetrahydrofuran, chloroform and carbon tetrachloride. The temperature conditions can also be varied over a wide range (for example, from -10°C to the reflux temperature of the reaction mixture). The compound represented by formula (1) can be further prepared by combining formula (■) and the corresponding alcohol or aldehyde represented by formula (■) with a suitable amine RNH2 at a temperature of 1(s) or less in the presence of nickel peroxide. can be prepared directly by reaction in an inert liquid medium such as ether, benzene, tetrahydrofuran or petroleum hydrocarbons.
ただしXは式(1)と同じ意味を有する。However, X has the same meaning as in formula (1).
式(1)で示される化合物はまた、式(V)R.NH.
W〔ただしwは脱離基たとえば−CO.H(ホルムアミ
ド)、−CO.アルキルでアルキルがたとえば1ないし
4個の炭化水素を有するもの(アミド)、−CONH2
(尿素)、−CONHR2ただしRは式(1)に定める
ものとする(置換された尿素)、−COO.アルキル(
アルキル基中に1−4個の炭素原子を有するウレタンで
ある)〕で示されるアミドを、式(■)て示される酸ま
たはその反応性誘導体たとえば酸無水物または酸ハライ
ドと反応させることにより製造できる。The compound represented by formula (1) also has the formula (V)R. N.H.
W [where w is a leaving group such as -CO. H (formamide), -CO. Alkyl having, for example, 1 to 4 hydrocarbons (amide), -CONH2
(urea), -CONHR2, where R is defined in formula (1) (substituted urea), -COO. Alkyl (
A urethane having 1-4 carbon atoms in the alkyl group) is produced by reacting an amide represented by the formula (■) with an acid represented by the formula (■) or a reactive derivative thereof such as an acid anhydride or an acid halide. can.
無水物を用いる場合は、触媒量の硫酸を含むのが好まし
い。各反応物を液体媒質中で共に加熱するとよい。式(
1)で示される化合物を製造するさらなる方法は、式(
■)で示される化合物からの水、ハロゲン化水素または
ハロゲン分子の脱離である。ただし式中、AおよびBは
同一で共にハロであるか、AかBの一方がハロまたはヒ
ドロキシであり、他方が水素であり、XおよびRは上記
式(1)に定めるものとする。たとえば式(■)で示さ
れるα−またはβ−ヒドロキシ化合物からの水の脱離は
、脱水剤たとえば塩基(たとえば水性水酸化ナトリウム
)または濃硫酸またはポリリン酸との反応により実施で
きる。モノハロ中間生成物を塩基(たとえば水酸化カリ
ウムまたはジメチルアニリン)で処理するか、あるいは
単に加熱してハロゲン化水素を遊離する。ジハロ中間生
成物を、たとえば亜鉛およびエタノールで還元するか、
またはヨウ化カリウムで処理してジヨード化合物となし
、続いてヨウ素分子を遊離する。式(■)で示される中
間酸は古典的な有機合成法たとえばパーキン合成(Pe
rkinSynthesjs)、レフオレマツキー反応
(RefOrmatskyreactiOn)およびク
ネフエナーゲル縮合(KnOevenagelCOrK
lensatiOn)により製造できる。式(1)で示
される化合物は、咄乳動物たとえばマウス、犬および猫
、またさらに重要なことには人間のけいれんの治療また
は予防に使用できる。If an anhydride is used, it is preferred to include a catalytic amount of sulfuric acid. Each reactant may be heated together in a liquid medium. formula(
A further method for preparing compounds of formula (1) is
(2) Elimination of water, hydrogen halide, or halogen molecules from the compound shown in (2). However, in the formula, A and B are the same and both are halo, or one of A and B is halo or hydroxy and the other is hydrogen, and X and R are defined in the above formula (1). For example, elimination of water from the α- or β-hydroxy compound of formula (■) can be carried out by reaction with a dehydrating agent such as a base (eg aqueous sodium hydroxide) or concentrated sulfuric acid or polyphosphoric acid. The monohalo intermediate is treated with a base (eg potassium hydroxide or dimethylaniline) or simply heated to liberate the hydrogen halide. reducing the dihalo intermediate with, for example, zinc and ethanol;
Alternatively, it is treated with potassium iodide to form a diiodo compound, followed by liberating iodine molecules. The intermediate acid represented by formula (■) can be obtained using classical organic synthesis methods such as Perkin synthesis (Pe
rkinSynthesjs), RefOrmatskyreactiOn and KnOevenagel condensation (KnOevenagelCOrK)
lensatiOn). The compounds of formula (1) can be used for the treatment or prevention of convulsions in mammals such as mice, dogs and cats, and more importantly in humans.
この化合物は特に大発作、小発作、精神運動的てんかん
および病巣発作の治療に使用できる。3−トリフルオロ
メチルーベーシクロプロピルシナマミドが、その抗けい
れん特性により特に有用である。This compound can be used in particular for the treatment of grand mal mal seizures, petit mal mal seizures, psychomotor epilepsy and focal seizures. 3-Trifluoromethyl-bacyclopropylcinamamide is particularly useful due to its anticonvulsant properties.
式(1)で示される化合物、特に3−フルオローペーシ
クロプロピルシナマミドはまた、骨格筋肉の強直を低下
させるのに使用できる。Compounds of formula (1), particularly 3-fluoropecyclopropylcinamamide, can also be used to reduce skeletal muscle rigidity.
たとえばこれは、骨格筋肉の強直による疾病に伴うけい
れん、緊張過多および運動過多症状の治療または予防に
おいて、骨格筋肉を弛緩させるべく使用できる。この化
合物は特に、パーキンソン氏病、舞踏病、関節炎、アテ
トーゼ、てんかん症状、強縮(筋の持続的強直)および
特に筋肉けいれんの代わりにおこる縮瞳、を椎炎、脳性
麻痺状態および複合硬化症のような症状の治療および対
症療法に使用できる。けいれんの治療または予防や筋肉
強直の低下の為に、式(1)で示される化合物は1日に
1体重Kgあたり2から200m9までの服用量で使用
できる。For example, it can be used to relax skeletal muscles in the treatment or prevention of spasm, hypertonicity and hypermobility symptoms associated with diseases of skeletal muscle stiffness. This compound is particularly effective in treating Parkinson's disease, chorea, arthritis, athetosis, epilepsy, tetany (continuous stiffness of muscles) and especially miosis instead of muscle spasms, spondylitis, cerebral palsy conditions and multiple sclerosis. It can be used for the treatment of symptoms such as and symptomatic therapy. For the treatment or prevention of spasms and the reduction of muscle stiffness, the compounds of formula (1) can be used in doses of 2 to 200 m9 per kg body weight per day.
最適服用量は当然化合物の性質や患者の症状、また投与
方法により変化するが、好ましい服用量は1日に体重1
kgあたり20から60mgまでの範囲であり、30か
ら50m9までが最良である。所望の1日分の服用量を
、3回分の服用量にわけて投与するのが好ましい。好都
合な投与形態の一例として、それぞれ100から50b
9までの式(1)で示される化合物を含有する錠剤をあ
げる。医療上の使用において式(1)で示される化合物
は純粋な化学物質として投与できるが、好ましくは許容
可能な担体と共に医薬組成物として与えられる。The optimal dose naturally varies depending on the nature of the compound, the patient's symptoms, and the method of administration, but the preferred dose is 1 body weight per day.
It ranges from 20 to 60 mg per kg, best from 30 to 50 m9. Preferably, the desired daily dose is administered in three divided doses. As an example of a convenient dosage form, 100 to 50 b
Tablets containing compounds of formula (1) up to 9 are given below. Although in medical use the compounds of formula (1) can be administered as pure chemicals, they are preferably presented as a pharmaceutical composition together with an acceptable carrier.
かかる担体は当然組成物中の他の成分と相い入れ、かつ
服用者に対して有毒でないという意味において1許容可
能ョでなくてはならない。担体は固体または液体、ある
いは固体物質と液体物質の混合物であり、式(1)で示
される化合物を含有して、たとえば経口投与または直腸
での座薬投与用の錠剤、カプセルまたはカシエ剤として
の単位服用量組成物に処方するのが好ましい。本発明に
よる組成物中に他の医薬活性成分が存在してもよく、ま
たこの組成物は基本的に各成分を混合することよりなる
任意の既知の製薬技術により処方できる。経口、直腸ま
たは非経口投与(下記参照)における単位服用量組成物
は、式(1)で示される化合物の100ないし500m
gの範囲の量を含有するのがよい。経口投与用として、
化合物の細粒または顆粒は希釈剤、分散剤または表面活
性剤を含み、水またはシロツプ中でのドラフトにしても
よい。Such carrier must, of course, be acceptable in the sense of being compatible with the other ingredients in the composition and not toxic to the recipient. The carrier may be a solid or a liquid, or a mixture of solid and liquid substances, containing the compound of formula (1) in units such as tablets, capsules or cachets for oral or rectal administration. Preferably, it is formulated into a dosage composition. Other pharmaceutically active ingredients may be present in the composition according to the invention, and the composition can be formulated by any known pharmaceutical technique consisting essentially of mixing the ingredients. Unit dose compositions for oral, rectal or parenteral administration (see below) may contain 100 to 500 m of a compound of formula (1).
It is preferable to contain an amount in the range of .g. For oral administration,
Granules or granules of the compound may contain diluents, dispersants or surfactants and may be drafted in water or syrup.
カプセルまたは力シューは乾燥状態であるか、もしくは
懸濁剤を含んで水性または非水性サスペンションとなす
。錠剤の場合は活性成分の顆粒と希釈剤とを、結合剤と
滑沢剤と共に圧縮して製造するのが好ましい。フレーバ
ー剤、保存剤、懸濁剤、濃化剤および乳化剤を含んで、
水またはシロツプ中のサスペンション、または油型や水
/油型のエマルジョンとしてもよい。顆粒または錠剤は
被衣することもでき、また錠剤に刻み目をつけてもよい
。非経口投与用(筋肉内または腹膜内注射)として、化
合物を単位服用量または複数回分服用量を含有するとこ
ろの、化合物を血液と等張となすべく酸化防止剤、バッ
ファー、細菌安定化物質および溶質を含有する水性また
は非水性注入溶液、あるいは懸濁剤および濃化剤を含む
場合は水性また.は非水性のサスペンションとなす。救
急用の注入溶液およびサスペンションは、希釈剤、分散
剤および表面活性剤、結合剤および滑沢剤を含有する無
菌の粉末、顆粒または錠剤から製造できる。以上の記述
より我々が本発明について特許請求5する範囲は、本文
中に記す任意の新規の特色であり、主として以下よりな
るがこの他を排除するものではないことが理解されよう
。(a)上記に定める式(1)で示される新規の化合物
。Capsules or capsules may be dry or may include suspending agents to form an aqueous or non-aqueous suspension. Tablets are preferably prepared by compressing granules of the active ingredient and a diluent together with binders and lubricants. Including flavoring agents, preservatives, suspending agents, thickening agents and emulsifying agents,
It may be a suspension in water or syrup, or an oil or water/oil emulsion. The granules or tablets may be coated or the tablets may be scored. For parenteral administration (intramuscular or intraperitoneal injection), the compound contains unit doses or multiple doses of the compound, including antioxidants, buffers, bacterial stabilizing substances, and the like to make the compound isotonic with the blood. Aqueous or non-aqueous injection solutions containing solutes, or aqueous or non-aqueous injection solutions containing suspending and thickening agents. is made with a non-aqueous suspension. Emergency infusion solutions and suspensions can be prepared from sterile powders, granules or tablets containing diluents, dispersants and surfactants, binders and lubricants. From the above description, it will be understood that the scope of the present invention as claimed in Claim 5 is any novel feature described in the text, and mainly consists of the following, but does not exclude others. (a) A novel compound represented by formula (1) defined above.
(b) トランス構造を有するところの、上記に定める
式(1)で示される新規の化合物。(c)任意の既知の
方法、特にm−X−PhCH=CHCO2Hなる酸また
はその反応性誘導体と、式R,NH,W(ただしWは脱
離基でありRおよびxは式(1)に定めるものとする)
で示される化合物との反応を含む上記に記載の方法によ
る。(b) A novel compound having a trans structure and represented by the formula (1) defined above. (c) by any known method, in particular with the acid m-X-PhCH=CHCO2H or its reactive derivative; )
According to the method described above including reaction with a compound represented by.
式(1)で示される新規の化合物の合成。(d)式(1
)で示される化合物と医薬上許容可能な担体よりなる医
薬組成物。Synthesis of a novel compound represented by formula (1). (d) Formula (1
) and a pharmaceutically acceptable carrier.
(e)人間を含む啼乳動物に抗けいれんに有効で非毒量
の式(1)で示される化合物を投与するこl とよりな
る、前記啼乳動物に対するけいれんの治療または予防方
法。(e) A method for treating or preventing convulsions in mammals, including humans, which comprises administering to the mammals, including humans, an effective and non-toxic amount of the compound represented by formula (1).
(f)人間を含む咄乳動物に非毒性で強直低下に有効量
の式(1)で示される化合物を投与することよりなる、
前記啼乳動物に対する骨格筋肉の強直低下方法。(f) comprising administering to mammalian animals, including humans, a non-toxic and effective amount of the compound represented by formula (1) in reducing tetanus;
The method for reducing skeletal muscle tonicity in a crying mammal.
以下の諸例により本発明を例示するが、これによりいか
なる制限をも施すものではない。The invention is illustrated by the following examples without any restriction being imposed thereby.
温度はすべて摂氏にてあられす。例1
トランス3−ブロモーN−シクロプロピルシナマミドト
ランス3−ブロモケイ皮酸(M.p.l77−1790
;11.4f)、塩化チオニル(11.9f)およびド
ライベンゼン(150m1)の混合物を2時間加熱還流
した。All temperatures are in degrees Celsius. Example 1 Trans-3-bromo N-cyclopropylcinamamide trans-3-bromocinnamic acid (M.p.l77-1790
; 11.4f), thionyl chloride (11.9f) and dry benzene (150ml) was heated under reflux for 2 hours.
溶媒と塩化チオニルの過剰分とを減圧下で留去すると、
トランス3−プロモシナモイルクロリド(12.2f)
B.p.lOO−100.5還/0.2mHfが残つた
。トランス3−プロモシナモイルクロリド(12.2f
)をドライトルエン(150m1)中に溶かした溶液を
急速な攪拌下にて、シクロプロピルアミン(6.3y)
のドライトルエン(150m1)溶液中に1滴ずつ速く
加えた。When the solvent and excess thionyl chloride are distilled off under reduced pressure,
Trans-3-promosinamoyl chloride (12.2f)
B. p. lOO-100.5 reflux/0.2 mHf remained. Trans-3-promosinamoyl chloride (12.2f
) in dry toluene (150ml) was mixed with cyclopropylamine (6.3y) under rapid stirring.
was quickly added drop by drop into a solution of dry toluene (150 ml).
反応混合物を室温にて2時間攪拌し、次に30−35℃
にてさらに1時間攪拌した。溶媒と過剰分のアミンを減
圧下で除去した。残留物を水でこねて、シクロプロピル
アミンヒドロクロリドを除去した。生成物をp過し、希
塩酸で洗浄し次に水洗した。続いてこれをエタノールニ
水(1:10)より再結晶すると、白色結晶状のトラン
ス3−ブロモーN−シクロプロピルシナマミド(M.p
.llO−111ロ)を与えた。元素分析、NMRおよ
びIRのデータはすべて先述の構造と一致した。TLC
はシリカゲル上で5:1および3:1ヘキサンニエタノ
ールを用いて展関して、1個のスポットを与えた。例2
トランス3−フルオローN−シクロプロピルシナマミド
3−フルオロベンズアルデヒド(40y)、マロン酸(
47f)、およびピリジン(10f)とピペリジン(5
f)を含有するエタノール溶液(150m1)の混合物
を、攪拌下で8時間加熱還流した。The reaction mixture was stirred at room temperature for 2 hours and then heated to 30-35°C.
The mixture was further stirred for 1 hour. Solvent and excess amine were removed under reduced pressure. The residue was triturated with water to remove cyclopropylamine hydrochloride. The product was filtered, washed with dilute hydrochloric acid and then water. Subsequently, this was recrystallized from ethanol and water (1:10) to obtain white crystalline trans-3-bromo N-cyclopropylcinamamide (M.p.
.. llO-111b) was given. Elemental analysis, NMR and IR data were all consistent with the previously described structure. T.L.C.
was developed on silica gel using 5:1 and 3:1 hexane diethanol to give one spot. Example 2 Trans-3-fluoro N-cyclopropylcinamamide 3-fluorobenzaldehyde (40y), malonic acid (
47f), and pyridine (10f) and piperidine (5
A mixture of ethanol solution (150 ml) containing f) was heated to reflux for 8 hours under stirring.
反応混合物を冷却し水(300mL)を加えると、結晶
したトランス3−フルオロケイ皮酸を与えたので、これ
をろ過して除き、水洗し乾燥した。トランス3−フルオ
ロケイ皮酸(M.p.l62−163を収率84%にて
得た。トランス3−フルオロケイ皮酸(32.3y)、
塩化チオニル(48y)およびドライベンゼン(300
m1)の混合物を2時間加熱還流した。The reaction mixture was cooled and water (300 mL) was added to give crystallized trans-3-fluorocinnamic acid, which was filtered off, washed with water, and dried. Trans-3-fluorocinnamic acid (M.p.l62-163 was obtained in a yield of 84%. Trans-3-fluorocinnamic acid (32.3y),
Thionyl chloride (48y) and dry benzene (300
The mixture of m1) was heated under reflux for 2 hours.
溶媒と塩化チオニルの過剰分とを減圧下で留去すると、
トランス3−フルオロシナモイルクロリドが油状物とし
て残つた。トランス3−フルオロシナモイルクロリド(
3.3y)をドライトルエン(100m1)中に溶かし
た溶液を、シクロプロピルアミン(2.5y)のドライ
エーテル(100m1)溶液中に、環境温度にて攪拌し
ながら加えた。When the solvent and excess thionyl chloride are distilled off under reduced pressure,
Trans-3-fluorocinamoyl chloride remained as an oil. Trans-3-fluorocinamoyl chloride (
A solution of 3.3y) in dry toluene (100ml) was added to a solution of cyclopropylamine (2.5y) in dry ether (100ml) at ambient temperature with stirring.
この反応混合物を30−34てに2時間加熱し、溶媒と
過剰のアミンを減圧下で除去した。残留物を水でこね、
ろ過してエタノールニ水(1:10)より再結晶すると
、トランス3一フルオローN−シクロプロピルシナマミ
ド(M.p.9O−91ロ)を与えた。元素分析、NM
RおよびIRは構造を証明した。TLCはシリカゲル上
で5:1および3:1ヘキサンニエタノールを用いて展
関して、1個のスポットを与えた。例3
トランス3−トリフルオロメチルーN−シシクロプロピ
ルシナマミド例2に記すのと同様の方法を用いて、3,
一トリフルオロメチルシナモイルクロリドをシクロプロ
ピルアミンと反応させ、トランス3−トリフルオロメチ
ル0N0シクロプロピルシナマミド(M.p.730)
与えた。The reaction mixture was heated at 30-34 ℃ for 2 hours and the solvent and excess amine were removed under reduced pressure. Knead the residue with water;
Filtration and recrystallization from ethanol/water (1:10) gave trans-3-fluoro-N-cyclopropylcinamamide (M.p.9O-91ro). Elemental analysis, NM
R and IR verified the structure. TLC was performed on silica gel using 5:1 and 3:1 hexane diethanol to give one spot. Example 3 Trans-3-trifluoromethyl-N-cyclopropylcinamamide Using a method similar to that described in Example 2, 3,
Monotrifluoromethylcinnamoyl chloride is reacted with cyclopropylamine to produce trans-3-trifluoromethyl0N0cyclopropylcinamamide (M.p.730).
Gave.
例4
トランス3−ブロモーN−1S0θブチルシナマミド例
2および3と同様の方法を用いて、3−プロモシナモイ
ルクロリドをIsOブチルアミンと反応させ、トランス
3−ブロモON−ISOブチルシナマミド(M.p.l
O4−105I)を与えた。Example 4 Trans 3-bromo N-1S0θ Butylcinamamide Using a method similar to Examples 2 and 3, 3-promosinamoyl chloride was reacted with IsO butylamine to produce trans 3-bromoON-ISO butylcinamamide (M.p.l
O4-105I) was given.
例5トランス3−フルオローN−シナマミド
3−フルオロベンズアルデヒド(40y)、マロン酸(
47f)、およびピリジン(10y)とピペリジン(5
f)を含有するエタノール溶液(150m1)の混物を
攪拌下で8時間加熱還流した。Example 5 Trans-3-fluoro-N-cinamamide 3-fluorobenzaldehyde (40y), malonic acid (
47f), and pyridine (10y) and piperidine (5
A mixture of ethanol solution (150 ml) containing f) was heated to reflux under stirring for 8 hours.
反応混合物を冷却し水(300m1)を加えると、結晶
したトランス3−フルオロケイ皮酸を与えたので、これ
をろ過して除去し水洗して乾燥した。トランス3−フル
オロケイ皮酸(M.p.l62−163し)を得た。ト
ランス3−フルオロケイ皮酸(32.3y)、塩化チオ
ニル(48g)およびドライベンゼン(300m1)の
混合物を2時間加熱還流した。The reaction mixture was cooled and water (300ml) was added to give crystallized trans-3-fluorocinnamic acid which was filtered off, washed with water and dried. Trans-3-fluorocinnamic acid (M.p.162-163) was obtained. A mixture of trans-3-fluorocinnamic acid (32.3y), thionyl chloride (48g) and dry benzene (300ml) was heated under reflux for 2 hours.
溶媒と過剰の塩化チオニルを減圧下で留去すると、トラ
ンス3−フルオロシナモイルクロリドが油状物として残
つた。トランス3−フルオロシナモイルクロリド(5.
7g)をドライトルエン(50mL)中に溶かした溶液
中に、ドライアンモニアを塩化アンモニウムが形成しな
くなるまで、急速に攪拌しながらゆつくりと通じた。The solvent and excess thionyl chloride were distilled off under reduced pressure, leaving trans-3-fluorocinamoyl chloride as an oil. trans-3-fluorocinamoyl chloride (5.
Dry ammonia was slowly passed into a solution of 7 g) in dry toluene (50 mL) with rapid stirring until no ammonium chloride was formed.
反応混合物を環境温度にてさらに3紛間攪拌した。次に
溶媒と過剰のアンモニアを減圧下で除去し、残留成物を
水でこねた。エタノールニ水(1:10)より再結晶す
ると、トランス3−フルオロシナマミド(M.p.l2
l−122与えた。元素分析、NMRおよびIRのデー
タは先述の構造と一致した。TLCはシリカゲル上で5
:1および3:1ヘキサンニエタノールを用いて、1個
のスポットを与えた。例6
以下の各成分より座薬を処方した。The reaction mixture was stirred at ambient temperature for an additional three pulses. The solvent and excess ammonia were then removed under reduced pressure and the residual product was triturated with water. When recrystallized from ethanol and water (1:10), trans-3-fluorocinamamide (M.p.l2
I gave 1-122. Elemental analysis, NMR and IR data were consistent with the previously described structure. TLC on silica gel
:1 and 3:1 hexane diethanol were used to give one spot. Example 6 A suppository was prescribed from each of the following ingredients.
トランス3−トリフルオロメチルーベー
シクロプロピルシナマミド 30019カ
カオバター 200?9例7
以下の各成分をソフトゼラチンカプセルに充填した。Trans-3-trifluoromethyl-basic cyclopropylcinamamide 30019 Cocoa butter 200?9 Example 7
The following ingredients were filled into soft gelatin capsules.
トランス3−トリフルオロメチルーベー
シクロプロピルシナマミド 300m9ラ
クトース 75WL9コー
ンスターチ 20mg溶解シリ
カ 2]F!9ステアリン
酸マグネシウム 31!9例8以下の各成
分よりシロツプサスペンジヨンを製造した。Trans-3-trifluoromethyl-basiccyclopropylcinamamide 300m9 Lactose 75WL9 Cornstarch 20mg Dissolved Silica 2]F! 9 Magnesium Stearate 31!9 Example 8 A syrup suspension was produced from each of the following ingredients.
トランス3−トリフルオロメチルーNーシクロプロピル
シナマミド 300WL9ナトリウムカル
ボキシメチルセルロース
20TrL9微結晶状セルロース
1007F!9グリセリン
500m9ポリソルベート8010m1フレーバ
ー剤 適量保存在
0.1%シヨ糖シロツプ
5m1までの適量例9以下より圧縮錠剤を製造した
。Trans-3-trifluoromethyl-N-cyclopropylcinamamide 300WL9 Sodium carboxymethylcellulose
20TrL9 Microcrystalline cellulose
1007F! 9 Glycerin
500m9 Polysorbate 8010ml Flavoring agent present in appropriate amount
0.1% sucrose syrup
Compressed tablets were produced from Example 9 and below in suitable amounts up to 5 ml.
トランス3−トリフルオロメチルーN−
シクロプロピルシナマミド 300m9コ
ーンスターチ 50Tn9微結
晶状セルロース 50m9ステアリ
ン酸 4mgステアリン酸マ
グネシウム 1mg溶解シリカ
1Tn9例10以下の各成分をソフ
トゼラチンカプセルに充填した。Trans 3-trifluoromethyl-N-cyclopropylcinamamide 300m9 Corn starch 50Tn9 Microcrystalline cellulose 50m9 Stearic acid 4mg Magnesium stearate 1mg Dissolved silica
1Tn9 casesThe following 10 ingredients were filled into soft gelatin capsules.
トランス3−フルオローベーシクロプロ
ピルシナマミド 300m9.ラ
クトース 75m9コーン
スターチ 20m9溶解シリカ
2U9ステアリング酸マ
グネシウム 3m9例11以下の各成分から
シロツプサスペンジヨンを製造した。Trans-3-fluorobasic cyclopropylcinamamide 300m9. Lactose 75m9 Cornstarch 20m9 Dissolved Silica
2U9 Magnesium stearate 3m9 Example 11 A syrup suspension was manufactured from each of the following ingredients.
トランス3−ブロモーN−シクロプロピルシナマミド
300m9ナトリウムカルボキ
シメチルセルロース
20W!9微結晶状セルロース
100m9グリセリン 500
Tn9ポリソルベート8010m1フレーバー剤
適量保存剤
0.1%シヨ糖シロツプ 5m1
までの適量例12以下の各成分よりシロツプサスペンジ
ヨンを製造した。trans-3-bromo N-cyclopropylcinamamide
300m9 sodium carboxymethylcellulose
20W! 9 Microcrystalline cellulose
100m9 glycerin 500
Tn9 polysorbate 8010ml flavoring agent
Appropriate amount of preservative
0.1% sucrose syrup 5ml
Suitable Amount Example 12 A syrup suspension was manufactured from each of the following components.
トランス3−フロオローΔ−シクロプロピルシナマミド
300mgナトリウムカルボ
キシメチルセルロース
20WLg微結晶状セルロース
100m9グリセリン 5
00m9ポリソルベート8010m1フレーバー剤
適量保存剤
0.1%シヨ糖シロツプ 5m
1までの適量例13以下より圧縮錠剤を製造した。trans-3-fluoroΔ-cyclopropylcinamamide
300mg sodium carboxymethyl cellulose
20WLg microcrystalline cellulose
100m9 glycerin 5
00m9 polysorbate 8010m1 flavoring agent
Appropriate amount of preservative
0.1% sugar syrup 5m
Compressed tablets were prepared from Examples 13 and below.
トランス3−ブロモーN−シクロプロピ
ルシナマミド 30077!9
コーンスターチ 50WL,
微結晶状セルロース 50mgス
テアリン酸 47F19ステ
アリン酸マグネシウム 1Tn9溶解シリ
カ 1即例14以下の各成
分より圧縮錠剤を製造した。Trans-3-bromo N-cyclopropylcinamamide 30077!9
Cornstarch 50WL,
Microcrystalline cellulose 50mg Stearic acid 47F19 Magnesium stearate 1Tn9 Dissolved silica 1 Example 1 Compressed tablets were manufactured from each of the following ingredients.
トランス3−フルオローベーシクロプロ
ピルシナマミド 300mgコー
ンスターチ 50Tn9微結晶
状セルロース 507F!9ステア
リン酸 4WL9ステアリン
酸マグネシウム 1mg溶解シリカ
1Tn9例15抗けいれん活性
先述のMES薬理実験において、下記の各化合物はマウ
スに腹膜内投与すると以下のED5Oを有した。Trans-3-fluorobasic cyclopropylcinamamide 300mg cornstarch 50Tn9 microcrystalline cellulose 507F! 9 Stearic acid 4WL9 Magnesium stearate 1mg Dissolved silica
1Tn9 cases 15 Anticonvulsant activity In the above-mentioned MES pharmacology experiment, each of the following compounds had the following ED5O when administered intraperitoneally to mice.
化合物 ED5O(W!9/K9)
トランス3−フルオローN−シクロプロピルシナマミド
60トランス3−ブロモー封−
シクロプロピルシナマミド 7
7トランス3−トリフルオロメチルー人一ンクロプロピ
ルシナマミド 56トランス3−ブロモーN
−1S0ブチルシ犬マミド
46トランス3−フルオロシナマミド 関列1
6筋肉弛緩活性
3−フルオローペーシクロプロピルシナマミドD中枢作
用の筋肉弛緩効果は、Ber?R,F.M.およびBr
adley,W.(Br.J.Pharmac.l〕H
emOther.l94岬、第1巻、265−272頁
)、およびCrankshaw,D.P.およびRap
er,C.(Br.J.)Harmac.l97O年、
第詔巻、148−156頁)に記載D方法に基いて決定
した。Compound ED5O (W!9/K9)
trans-3-fluoro-N-cyclopropylcinamamide
60 transformer 3-bromo seal-
Cyclopropylcinamamide 7
7 trans 3-trifluoromethyl-cyclopropylcinamamide 56 trans 3-bromo N
-1S0 butyl dog mamid
46 trans-3-fluorocinamamide Relationship 1
6 Muscle Relaxation Activity 3-Fluoropecyclopropylcinamamide D Centrally acting muscle relaxing effect is Ber? R.F. M. and Br
adley, W. (Br.J.Pharmac.l)H
emOther. 194 Cape, Vol. 1, pp. 265-272) and Crankshaw, D. P. and Rap
er,C. (Br.J.) Harmac. 1970,
It was determined based on method D described in vol. 148-156).
この化合物は100−150n9/K9の経口服用量に
おいて、猫に対して単神経,車接構造の膝蓋健反射には
影響を与えることなし・こ、多神経連接構造の反射収縮
を抑制した。列17トランス3−トリフルオロメチルシ
ナモイルクロリド(8.5ダ)を無水トルエン(150
m1)中に溶;/))した溶液を、シクロプロピルアミ
ン(5y)の無水トルエン(100mt)溶液中に加え
た。At an oral dose of 100-150n9/K9, this compound did not affect the patellar reflex of the mononeuronal, contact structure in cats, but suppressed the reflex contraction of the multineural connecting structure. Column 17 Trans-3-trifluoromethylcinnamoyl chloride (8.5 Da) was dissolved in anhydrous toluene (150 Da).
The solution of cyclopropylamine (5y) in anhydrous toluene (100mt) was added to the solution of cyclopropylamine (5y) in anhydrous toluene (100mt).
反応混合物を室温にて数時間放置した。溶媒と過剰のア
ミンを減圧下に除去した。残留物を水で充分こね、エタ
ノール/水(1/15)より再結晶する;と、トランス
3−トリフルオロメチルーN−シクロプロピルシナマミ
ド(M.p.98℃)を与えた。元素分析ならびにNM
RおよびIRのスペクトルは、構造を証明した。例18
−54
例1の操作法に従い、以下に記すXおよびRを有する式
(1)で示される化合物を誘導体とする下記のシナマミ
ド誘導体類を製造した(すべてのケースにおいてNMR
,IRおよび元素分析はその溝造を証明した)。The reaction mixture was left at room temperature for several hours. Solvent and excess amine were removed under reduced pressure. The residue was thoroughly kneaded with water and recrystallized from ethanol/water (1/15) to give trans-3-trifluoromethyl-N-cyclopropylcinamamide (M.p. 98°C). Elemental analysis and NM
R and IR spectra verified the structure. Example 18
-54 Following the procedure of Example 1, the following cinamamide derivatives were prepared using the compound represented by formula (1) with X and R as shown below (in all cases, NMR
, IR and elemental analysis proved its structure).
Claims (1)
はフルオロまたはトリフルオロメチルであり、Rは3〜
6個の炭素原子を有するシクロアルキルである)で示さ
れトランス配置を有する化合物。 2 Xがフルオロである特許請求の範囲第1項の化合物
。 3 Rがシクロプロピルである特許請求の範囲第1項ま
たは第2項のいずれか一つの化合物。 4 トランス−3−フルオロ−N−シクロプロピルシナ
マミドである特許請求の範囲第1項の化合物。 5 トランス−3−トリフルオロメチル−N−シクロプ
ロピルシナマミドである特許請求の範囲第1項の化合物
。 6 式( I ) ▲数式、化学式、表等があります▼( I )(式中、X
はフルオロまたはトリフルオロメチルであり、そしてR
は3〜6個の炭素原子を有するシクロアルキルである)
で示され、トランス配置を有する化合物の製造方法であ
つて、式R−NH_2 (式中Rは前記と同じ意味を有する)のアミン化合物を
式(II)m−X−Ph−CH=CH−CO_2H(II)
(式中Xは前記と同じ意味を有する)の酸またはその反
応性誘導体と反応させることからなる方法。 7 式( I ) ▲数式、化学式、表等があります▼( I )(式中、X
はフルオロまたはトリフルオロメチルであり、そしてR
は3〜6個の炭素原子を有するシクロアルキルである)
で示され、トランス配置を有する化合物の製造方法であ
つて、式R−NH_2 (式中Rは前記と同じ意味を有する)のアミンを式(I
II)または(IV)▲数式、化学式、表等があります▼(
III)または▲数式、化学式、表等があります▼(IV)
(式中、RおよびXは前記と同じ意味を有する)でそれ
ぞれ示されるアルコールまたはアルデヒド化合物と過酸
化ニッケルおよび不活性液体媒質の存在下で温度10℃
以下において反応させることからなる方法。 8 式( I ) ▲数式、化学式、表等があります▼( I )(式中、X
はフルオロまたはトリフルオロメチルであり、そしてR
は3〜6個の炭素原子を有するシクロアルキルである)
で示され、トランス配置を有する化合物の製造方法であ
つて、式(V)R−NH−W(式中Rは前記と同じ意味
を有し、そしてWは脱離性基である)の化合物を式(I
I)m−X−Ph−CH=CH−CO_2H (式中Xは前記と同じ意味を有する)の酸またはその反
応性誘導体と反応させることを含む方法。 9 式( I ) ▲数式、化学式、表等があります▼( I )(式中Xは
フルオロまたはトリフルオロメチルであり、そしてRは
3〜6個の炭素原子を有するシクロアルキルである)で
示され、トランス配置を有する化合物の製造方法であつ
て、式(VI)▲数式、化学式、表等があります▼(VI)
(式中、AおよびBは同一であつてそれぞれハロである
か、またはAかBの一方がハロまたはヒドロキシであり
、他方が水素であり、RおよびXは前記と同じ意味を有
する)の化合物より水、ハロゲン化水素またはハロゲン
分子を脱離させることからなる方法。 10 式( I ) ▲数式、化学式、表等があります▼( I )(式中、X
はフルオロまたはトリフルオロメチルであり、そしてR
は3〜6個の炭素原子を有するシクロアルキルである)
で示され、トランス配置を有する化合物および医薬上使
用可能な担体を含む抗けいれん剤。 11 Xがフルオロである特許請求の範囲第10項の抗
けいれん剤。 12 Rがシクロプロピルである特許請求の範囲第10
項の抗けいれん剤。 13 式( I )の化合物がトランス−3−フルオロ−
N−シクロプロピルシナマミドである特許請求の範囲第
10項の抗けいれん剤。 14 式( I )の化合物がトランス−3−トリフルオ
ロメチル−N−シクロプロピルシナマミドである特許請
求の範囲第10項の抗けいれん剤。[Claims] 1 Formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) (In the formula,
is fluoro or trifluoromethyl, and R is 3-
cycloalkyl having 6 carbon atoms) and has a trans configuration. 2. A compound according to claim 1, wherein X is fluoro. A compound according to any one of claims 1 or 2, wherein 3 R is cyclopropyl. 4. The compound of claim 1 which is trans-3-fluoro-N-cyclopropylcinamamide. 5. The compound of claim 1 which is trans-3-trifluoromethyl-N-cyclopropylcinamamide. 6 Formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) (In the formula,
is fluoro or trifluoromethyl, and R
is cycloalkyl having 3 to 6 carbon atoms)
A method for producing a compound represented by the formula (II) m-X-Ph-CH=CH- CO_2H(II)
(wherein X has the same meaning as defined above) or a reactive derivative thereof. 7 Formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) (In the formula,
is fluoro or trifluoromethyl, and R
is cycloalkyl having 3 to 6 carbon atoms)
A method for producing a compound represented by the formula R-NH_2 (wherein R has the same meaning as above), which is an amine of the formula (I
II) or (IV) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(
III) or ▲There are mathematical formulas, chemical formulas, tables, etc.▼(IV)
(wherein R and
A method comprising reacting: 8 Formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) (In the formula,
is fluoro or trifluoromethyl, and R
is cycloalkyl having 3 to 6 carbon atoms)
A method for producing a compound represented by formula (V) R-NH-W (wherein R has the same meaning as above and W is a leaving group) to the formula (I
I) A process comprising reacting m-X-Ph-CH=CH-CO_2H with an acid or a reactive derivative thereof, in which X has the same meaning as above. 9 Formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (I) (wherein X is fluoro or trifluoromethyl and R is cycloalkyl having 3 to 6 carbon atoms) It is a method for producing compounds with trans configuration, and there are formula (VI) ▲ mathematical formulas, chemical formulas, tables, etc. ▼ (VI)
A compound of the formula (wherein A and B are the same and each is halo, or one of A or B is halo or hydroxy and the other is hydrogen, and R and X have the same meanings as above) A method consisting of eliminating water, hydrogen halide or halogen molecules. 10 Formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) (In the formula, X
is fluoro or trifluoromethyl, and R
is cycloalkyl having 3 to 6 carbon atoms)
An anticonvulsant agent comprising a compound having the trans configuration and a pharmaceutically acceptable carrier. 11. The anticonvulsant agent of claim 10, wherein X is fluoro. 12 Claim 10 in which R is cyclopropyl
Nuchal anticonvulsant. 13 The compound of formula (I) is trans-3-fluoro-
11. The anticonvulsant agent of claim 10 which is N-cyclopropylcinamamide. 14. The anticonvulsant agent of claim 10, wherein the compound of formula (I) is trans-3-trifluoromethyl-N-cyclopropylcinamamide.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB4169/76 | 1976-02-03 | ||
GB416976 | 1976-02-03 | ||
GB417076 | 1976-02-03 | ||
GB4168/76A GB1568401A (en) | 1976-02-03 | 1976-02-03 | Biologically active amides |
GB4168/76 | 1976-02-03 | ||
GB4170/76 | 1976-02-03 | ||
US71231876A | 1976-08-06 | 1976-08-06 | |
US71213576A | 1976-08-06 | 1976-08-06 | |
US71213476A | 1976-08-06 | 1976-08-06 | |
US712135 | 1976-08-06 | ||
US712318 | 1976-08-06 | ||
US712134 | 1976-08-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS52116437A JPS52116437A (en) | 1977-09-29 |
JPS6056700B2 true JPS6056700B2 (en) | 1985-12-11 |
Family
ID=27546490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52010599A Expired JPS6056700B2 (en) | 1976-02-03 | 1977-02-02 | Pharmaceutical compositions comprising new compounds, and methods for producing and using the same |
Country Status (20)
Country | Link |
---|---|
JP (1) | JPS6056700B2 (en) |
AR (1) | AR218865A1 (en) |
AT (1) | AT363926B (en) |
BE (1) | BE851020A (en) |
CA (1) | CA1109076A (en) |
CH (1) | CH634551A5 (en) |
CS (2) | CS245758B2 (en) |
DD (1) | DD130349A5 (en) |
DE (1) | DE2704365C2 (en) |
DK (1) | DK43177A (en) |
FI (1) | FI69625C (en) |
FR (1) | FR2340303A1 (en) |
GB (1) | GB1568401A (en) |
GR (1) | GR66474B (en) |
HU (1) | HU175435B (en) |
IE (1) | IE44862B1 (en) |
IL (1) | IL51373A (en) |
NL (1) | NL7701088A (en) |
PL (2) | PL119716B1 (en) |
SE (2) | SE436870B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0714871B2 (en) * | 1989-02-02 | 1995-02-22 | 大正製薬株式会社 | Muscle relaxant |
DE19931116A1 (en) * | 1999-07-06 | 2001-01-11 | Bayer Ag | Process for the production of phenethylamines and new chemical compounds |
CN104513172B (en) * | 2013-09-30 | 2018-02-02 | 天士力医药集团股份有限公司 | Acid amides alkaloid, preparation method and its medicinal usage containing trifluoromethyl |
CN104432097B (en) * | 2014-12-16 | 2016-08-17 | 广州渔夫堡医药科技有限公司 | A kind of natural enriching substance of alleviating physical fatigue |
-
1976
- 1976-02-03 GB GB4168/76A patent/GB1568401A/en not_active Expired
-
1977
- 1977-02-02 PL PL1977195740A patent/PL119716B1/en not_active IP Right Cessation
- 1977-02-02 CS CS777652A patent/CS245758B2/en unknown
- 1977-02-02 GR GR52690A patent/GR66474B/el unknown
- 1977-02-02 HU HU77WE549A patent/HU175435B/en not_active IP Right Cessation
- 1977-02-02 DE DE2704365A patent/DE2704365C2/en not_active Expired
- 1977-02-02 CH CH125377A patent/CH634551A5/en not_active IP Right Cessation
- 1977-02-02 SE SE7701107A patent/SE436870B/en not_active IP Right Cessation
- 1977-02-02 NL NL7701088A patent/NL7701088A/en not_active Application Discontinuation
- 1977-02-02 PL PL1977214782A patent/PL119314B1/en unknown
- 1977-02-02 IE IE212/77A patent/IE44862B1/en unknown
- 1977-02-02 IL IL51373A patent/IL51373A/en unknown
- 1977-02-02 BE BE174605A patent/BE851020A/en not_active IP Right Cessation
- 1977-02-02 FI FI770365A patent/FI69625C/en not_active IP Right Cessation
- 1977-02-02 JP JP52010599A patent/JPS6056700B2/en not_active Expired
- 1977-02-02 CA CA270,904A patent/CA1109076A/en not_active Expired
- 1977-02-02 DD DD7700197200A patent/DD130349A5/en not_active IP Right Cessation
- 1977-02-02 AR AR266409A patent/AR218865A1/en active
- 1977-02-02 FR FR7702865A patent/FR2340303A1/en active Granted
- 1977-02-02 AT AT0065277A patent/AT363926B/en not_active IP Right Cessation
- 1977-02-02 CS CS77695A patent/CS245756B2/en unknown
- 1977-02-02 DK DK43177A patent/DK43177A/en not_active Application Discontinuation
-
1983
- 1983-01-28 SE SE8300432A patent/SE8300432D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FI69625C (en) | 1986-03-10 |
DE2704365A1 (en) | 1977-08-04 |
FR2340303B1 (en) | 1979-04-13 |
AT363926B (en) | 1981-09-10 |
SE8300432L (en) | 1983-01-28 |
ATA65277A (en) | 1981-02-15 |
FI69625B (en) | 1985-11-29 |
GB1568401A (en) | 1980-05-29 |
NL7701088A (en) | 1977-08-05 |
DE2704365C2 (en) | 1986-03-20 |
DK43177A (en) | 1977-08-04 |
IL51373A (en) | 1981-12-31 |
PL119314B1 (en) | 1981-12-31 |
FR2340303A1 (en) | 1977-09-02 |
SE7701107L (en) | 1977-08-04 |
GR66474B (en) | 1981-03-23 |
IE44862B1 (en) | 1982-04-21 |
BE851020A (en) | 1977-08-02 |
CA1109076A (en) | 1981-09-15 |
SE436870B (en) | 1985-01-28 |
IL51373A0 (en) | 1977-04-29 |
DD130349A5 (en) | 1978-03-22 |
FI770365A (en) | 1977-08-04 |
CS245758B2 (en) | 1986-10-16 |
PL119716B1 (en) | 1982-01-30 |
PL195740A1 (en) | 1979-05-07 |
JPS52116437A (en) | 1977-09-29 |
SE8300432D0 (en) | 1983-01-28 |
IE44862L (en) | 1977-08-03 |
AR218865A1 (en) | 1980-07-15 |
CS245756B2 (en) | 1986-10-16 |
CH634551A5 (en) | 1983-02-15 |
HU175435B (en) | 1980-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69616056T2 (en) | 3-ACYLINDOLS AS CB2 RECEPTOR AGONISTS | |
US3600437A (en) | Substituted phenylalkanoic acids and derivatives thereof | |
JP3775796B2 (en) | Nitrate esters having anti-inflammatory activity and / or analgesic activity and methods for producing them | |
CH638520A5 (en) | METHOD FOR PRODUCING BENZAMIDE COMPOUNDS. | |
DE2100242A1 (en) | Substituted nitroimidazoles effective against trypanosomiasis | |
DE2836616A1 (en) | ALPHA -HALOGENMETHYL DERIVATIVES OF AMINES | |
JPH045029B2 (en) | ||
US4351770A (en) | Preparation of N(2-pyrrolidinylmethyl)2-methoxy-5-benzenesulfonamidobenzamides | |
US4243678A (en) | Acylhydrocarbylaminoalkanoic acids, compositions and uses | |
RU2129560C1 (en) | Adenosine derivatives, method of preparing thereof, pharmaceutical composition, and method of preparing thereof | |
JPS6056700B2 (en) | Pharmaceutical compositions comprising new compounds, and methods for producing and using the same | |
JPH0449533B2 (en) | ||
US4156002A (en) | Pharmaceutical compositions | |
CA1075714A (en) | Biologically active amides | |
JPS61215361A (en) | Antispasmodic | |
US20020173548A1 (en) | Halogenated antituberculosis agents | |
US4190674A (en) | 3-Fluoro-N-cyclopropylcinnamide | |
DE69717841T2 (en) | SUBSTITUTED N-ARYLMETHYLAMINO CYCLOBUTEN-3,4-DION DERIVATIVES | |
US4091112A (en) | Biologically active amides | |
US4826858A (en) | N-substituted aziridine-2-carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
DE69509510T2 (en) | 2- (AMINOALKOXY) PHENYLALKYLAMINE WITH INFLAMMATORY PROPERTIES | |
US3161680A (en) | Nu-alkyl-nu-benzyl-beta-thiopropionamides | |
DE69528984T2 (en) | INHIBITION OF LEUKOTRIA BIOSYNTHESIS BY URINE DERIVATIVES | |
US4562200A (en) | 5(Indolyl) and 5(2,3-dihydroindolyl) substituted aminoethanols and their use as anti-hypertensives | |
US4521606A (en) | 5-Indolyl substituted aminoethanols |